Journal Article

HCV/HIV-coinfection—is there a state of the art after APRICOT and RIBAVIC?

S. Mauss and J. K. Rockstroh

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 56, issue 4, pages 615-618
Published in print October 2005 | ISSN: 0305-7453
Published online August 2005 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dki277
HCV/HIV-coinfection—is there a state of the art after APRICOT and RIBAVIC?

Show Summary Details

Preview

Today hepatitis C is one of the unsolved medical problems and results in a significant number of deaths in the HIV population, particularly in southern Europe and the USA, where the prevalence of HCV/HIV-coinfection in the HIV population ranges from 30–50%. Recent trials using pegylated interferon alfa in combination with low dose ribavirin have achieved overall sustained response rates of up to 42%. However, high discontinuation rates, adverse events associated with mitochondrial toxicities or treatment of patients with advanced cirrhosis may decrease response to treatment and result in serious adverse events. Optimizing antiretroviral therapy before the start of interferon-based therapy and active management of adverse events will reduce complications and improve treatment success. The use of higher ribavirin doses and longer treatment periods should be systematically studied to improve hepatitis C therapy in coinfected patients in the near future.

Keywords: HCV; HIV; interferon; ribavirin; adverse events

Journal Article.  1716 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.